Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model

被引:62
|
作者
Iwasaki, M
Kuwata, T
Yamazaki, Y
Jenkins, NA
Copeland, NG
Osato, M
Ito, Y
Kroon, E
Sauvageau, G
Nakamura, T
机构
[1] Japanese Fdn Canc Res, Dept Carcinogenesis, Toshima Ku, Inst Canc, Tokyo 1708455, Japan
[2] NCI, Frederick Canc Res & Dev Ctr, Mouse Canc Genet Program, Frederick, MD USA
[3] Inst Mol & Cell Biol, Singapore, Singapore
[4] Oncol Res Inst, Singapore, Singapore
[5] Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stern Cells, Montreal, PQ H2W 1R7, Canada
关键词
D O I
10.1182/blood-2004-04-1508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The chromosomal translocation t(7; 11)(p15;p15), observed in human myeloid leukemia, results in a NUP98 and HOXA9 gene fusion. We generated a transgenic mouse line that specifically expressed the chimeric NUP98-HOXA9 gene in the myeloid lineage. While only 20% of the transgenic mice progressed to leukemia after a latency period, myeloid progenitor cells from nonleukemic transgenic mice still exhibited increased proliferative potential. This suggested that the NUP98-HOXA9 fusion induced a preleukemic phase, and other factors were required for complete leukemogenesis. NUP98-HOXA9 expression promoted the onset of retrovirus-Induced BXH2 myeloid leukemia. This phenomenon was used to identify cooperative disease genes as common integration sites (CISs). Meis1, a known HOX cofactor, was identified as a CIS with a higher integration frequency in transgenic than in wild-type BXH2 mice. By the same means we identified further 4 candidate cooperative genes, Dnalc4, Fcgr2b, Fcrl, and Con1. These genes cooperated with NUP98-HOXA9 in transforming NIH 3T3 cells. The system described here is a powerful tool to identify cooperative oncogenes and will assist in the clarification of the multistep process of carcinogenesis. (C) 2005 by The American Society of Hematology.
引用
收藏
页码:784 / 793
页数:10
相关论文
共 50 条
  • [11] The oncogene Nup98-HOXA9 acts as an aberrant transcription factor in myeloid cells.
    Yaseen, NR
    Takeda, A
    Camarata, T
    Moore, MAS
    Viale, A
    Ghannam, G
    BLOOD, 2003, 102 (11) : 851A - 851A
  • [12] Molecular Dissection of Nup98-HoxA9 Oncogenic Activity Using Drosophila.
    Therrien, Marc
    Laberge, Gino
    Koonpaew, Surapong
    Bidla, Gawa
    Sauvageau, Guy
    BLOOD, 2008, 112 (11) : 1295 - 1295
  • [13] Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression
    Sloma, Ivan
    Beer, Philip
    Desterke, Christophe
    Bulaeva, Elizabeth
    Bilenky, Misha
    Carles, Annaick
    Moksa, Michelle
    Raghuram, Kamini
    Brimacombe, Cedric
    Lambie, Karen
    Turhan, Ali G.
    Wagner-Ballon, Orianne
    Gaulard, Philippe
    Humphries, Keith
    Hirst, Martin
    Eaves, Connie J.
    HAEMATOLOGICA, 2021, 106 (03) : 881 - 885
  • [14] NUP98-HOXA9融合基因与白血病
    谢志尧
    陈竺
    国外医学输血及血液学分册., 2005, (03) : 201 - 203
  • [15] HOX-PBX interaction is not required for the induction of AML by NUP98-HOXA9 or HOXA9.
    Kroon, E
    Yao, J
    Sauvageau, G
    BLOOD, 2001, 98 (11) : 95A - 96A
  • [16] NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice
    Kroon, E
    Thorsteinsdottir, U
    Mayotte, N
    Nakamura, T
    Sauvageau, G
    EMBO JOURNAL, 2001, 20 (03): : 350 - 361
  • [17] A genetic screen in Drosophila uncovers the multifaceted properties of the NUP98-HOXA9 oncogene
    Gavory, Gwenaelle
    Baril, Caroline
    Laberge, Gino
    Bidla, Gawa
    Koonpaew, Surapong
    Sonea, Thomas
    Sauvageau, Guy
    Therrien, Marc
    PLOS GENETICS, 2021, 17 (08):
  • [18] Human NUP98-HOXA9 promotes hyperplastic growth of hematopoietic tissues in Drosophila
    Baril, Caroline
    Gavory, Gwenaelle
    Bidla, Gawa
    Knaevelsrud, Helene
    Sauvageau, Guy
    Therrien, Marc
    DEVELOPMENTAL BIOLOGY, 2017, 421 (01) : 16 - 26
  • [19] NUP98-HOXA9 drives High-Risk Myeloid Disease in Zebrafish - An In Vivo platform to Study Interacting Genes and Perform Drug Discovery
    Forrester, A. Michael
    Coombs, Andrew J.
    McBride, Eileen R.
    Chute, Ian
    Leger, Daniel
    Lewis, Stephen
    Grabher, Clemens
    Look, Thomas
    Berman, Jason N.
    BLOOD, 2011, 118 (21) : 1547 - 1547
  • [20] HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients
    Rio-Machin, Ana
    Gomez-Lopez, Gonzalo
    Maiques-Diaz, Alba
    Alvarez, Sara
    Calasanz, Maria Jose
    Fitzgibbon, Jude
    Cigudosa, Juan C.
    BLOOD, 2016, 128 (22)